- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: example 13 [WO2015132799A2]
Compound class: Synthetic organic
Comment: ZYBT1 is reported as a potent and irreversible Bruton's tyrosine kinase (BTK) inhibitor [1-2]. It is able to inhibit the ibrutinib-resistant BTKC481S mutant. ZYBT1 mediates anti-inflammatory activity in models of rheumatoid arthritis and has antiproliferative action against B-cell lymphoma xenograft tumours .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Desai RC, Bahekar R, Patel D, Shah K. (2015)
Novel heterocyclic compounds.
Patent number: WO2015132799A2. Assignee: Cadila Healthcare Limited. Priority date: 03/02/2014. Publication date: 11/09/2015.
2. Ghoshdastidar K, Patel H, Bhayani H, Patel A, Thakkar K, Patel D, Sharma M, Singh J, Mohapatra J, Chatterjee A et al.. (2020)
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Pharmacol Res Perspect, 8 (4): e00565. [PMID:32790160]